SAN RAMON, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) today announced that it has launched a new website, BePHenomenal.com, dedicated to educating and empowering people living with pulmonary hypertension (PH) to live their healthiest and most PHenomenal lives. SteadyMed is also sponsoring a Thunderclap, as well as a photo and video drive to recognize the strength and beauty within this community.
BePHenomenal.com will offer expert lifestyle information customized for people with PH, including exercise videos, healthy recipes and stories from people living with PH about how they manage their condition and refuse to let PH define them. People living with PH are encouraged to visit the site and register to receive updates as new information is added.
“Initial diagnosis and management of PH can be quite overwhelming to the patient, family or caregiver,” said Patricia Gresha, PH Nurse Practitioner and Program Coordinator, Fresno Pulmonary Hypertension Program. “BePHenomenal.com will help provide patients and their caregivers with health and wellness tools customized to their unique needs."
“As someone living with PH, it is important that I find ways to live my best life every day and carry out my personal motto, ‘it’s a great day to be alive,’” said Carol Bowling, PH patient. “The BePHenomenal.com website provides information about maintaining a healthy lifestyle by sharing wellness and exercise tips from PH patients and experts familiar with PH. I am inspired by this PHenomenal community, and am grateful to SteadyMed for continuing to help our voices be heard.”
As part of PH awareness activities in November, SteadyMed is inviting people with PH and their loved ones to join a Thunderclap celebrating the unique strength and beauty within the PH community. The Thunderclap will be issued on Thursday, Nov. 17 at 12 p.m. ET, and those interested in adding their voice in support can do so by signing up here or by pasting this link into your browser https://www.thunderclap.it/en/projects/49440-celebrate-your-phenomself. Thunderclap is an online tool that helps people rally together to spread a message on social media at the same time.
SteadyMed is also introducing a photo and video drive on Twitter and Facebook encouraging those affected by PH to share what they are thankful for this holiday season using the hashtag #PHenomSelf.
“SteadyMed is dedicated to supporting the PH community, and we hope that BePHenomenal.com helps empower and inspire this community to live their most PHenomenal lives,” said Marylyn Rigby, Senior Director, Investor Relations and Marketing at SteadyMed. “We are always excited to honor the incredible people in the PH community. We are especially grateful to do so during Pulmonary Hypertension Awareness month and look forward to sharing more amazing stories from members of this community through our Thunderclap and photo and video drive.”
PH is a condition defined as high blood pressure in the lungs. One form of PH, pulmonary arterial hypertension (PAH), is a progressive and life-changing chronic disease. Symptoms, which worsen over time and significantly impact patients’ lives, can include shortness of breath, dizziness and fatigue. There is no cure for the disease, which can become life-threatening within a few years if left untreated.
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed on November 14, 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.